RiverPark Advisors LLC Raises Stake in Artivion, Inc. (NYSE:AORT)

RiverPark Advisors LLC increased its stake in Artivion, Inc. (NYSE:AORT) by 151.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 5,387 shares of the company’s stock after buying an additional 3,246 shares during the quarter. RiverPark Advisors LLC’s holdings in Artivion were worth $143,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in shares of Artivion in the 2nd quarter worth about $28,000. Allspring Global Investments Holdings LLC lifted its holdings in Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after purchasing an additional 4,154 shares during the last quarter. RW Investment Management LLC purchased a new stake in Artivion during the second quarter valued at about $219,000. Intech Investment Management LLC purchased a new stake in Artivion during the second quarter valued at about $253,000. Finally, Tidal Investments LLC purchased a new stake in Artivion during the first quarter valued at about $257,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the transaction, the senior vice president now directly owns 161,932 shares in the company, valued at approximately $4,299,294.60. This represents a 1.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.10% of the stock is owned by company insiders.

Artivion Stock Down 1.3 %

Shares of AORT opened at $26.65 on Friday. The business’s 50-day moving average price is $26.34 and its 200-day moving average price is $25.36. Artivion, Inc. has a twelve month low of $13.42 and a twelve month high of $30.00. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Analyst Ratings Changes

Several research firms have commented on AORT. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Artivion in a report on Friday, September 27th. Stifel Nicolaus upped their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Oppenheimer upped their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, JMP Securities started coverage on Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $31.00.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.